KDI tripeptide from laminin: a novel approach to treat neurodegenerative disorders.
The excessive release of glutamate following brain injury is responsible for the phenomenon of glutamate excitotoxicity, mediated through glutamate receptors, resulting in apoptotic cell death. KDI ameliorates excitotoxicity and regenerates damaged nerve cells.
Carney
Steve
S
D006801:Humans; D007797:Laminin / Q000627:therapeutic use*; D019636:Neurodegenerative Diseases / Q000188:drug therapy*; D009842:Oligopeptides / Q000627:therapeutic use*; D010446:Peptide Fragments / Q000627:therapeutic use; D017434:Protein Structure, Tertiary; D018092:Kainic Acid Receptors / Q000037:antagonists & inhibitors; D000097806:GluK2 Kainate Receptor
D007797:Laminin; D009842:Oligopeptides; D010446:Peptide Fragments; D018092:Kainic Acid Receptors; D000097806:GluK2 Kainate Receptor